Your session is about to expire
← Back to Search
C1 esterase inhibitor
RUCONEST for Chronic Fatigue Syndrome
Phase 4
Waitlist Available
Research Sponsored by IMMUNOe Research Centers
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 17
Awards & highlights
Study Summary
This study is evaluating whether a drug may help improve neurological symptoms for individuals who have been infected with the SARS virus.
Eligible Conditions
- Chronic Fatigue Syndrome
- Coronavirus
- Post-Viral Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 17
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 17
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Immunological Biomarkers (Com)
Immunological Biomarkers (GAD)
Immunological Biomarkers (Ig)
+17 moreTrial Design
2Treatment groups
Active Control
Placebo Group
Group I: RUCONESTActive Control1 Intervention
IV Ruconest
Group II: PlaceboPlacebo Group1 Intervention
Placebo
Find a Location
Who is running the clinical trial?
IMMUNOe Research CentersLead Sponsor
3 Previous Clinical Trials
56 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger